Quintiles’ Anand Tharmaratnam Honored as ‘Asian Male Executive of the Year’ in BioPharma Asia Industry Awards 2015
March 24 2015 - 8:30PM
Business Wire
Since 2004, he has guided Quintiles to its
current market-leader position in Asia
Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., last
night was honored as “Best Life Science Asian Male Executive of the
Year” at the BioPharma Asia Industry Awards. Dr. Tharmaratnam was
selected in a vote of biopharmaceutical industry professionals from
five distinguished executives shortlisted for the award.
Quintiles Head of Asia Markets Anand
Tharmaratnam, M.D., accepts 'Asian Male Executive of the Year'
honors at the BioPharma Asia Industry Awards dinner Tuesday night
(24 March) in Singapore. (Photo: Business Wire)
“On behalf of the hundreds of voters who made their voices heard
in the competition, we are pleased to present this award to Dr.
Tharmaratnam,” said Sharon Roessen, Managing Director of Terrapinn
Pte Ltd, organizer of BioPharma Asia Convention 2015. “His
visionary leadership and Quintiles’ stellar work were frequent
themes in voter comments. We would like to thank Anand for his
contributions to advancing Asia’s biopharma industry.”
Over the past 11 years, Dr. Tharmaratnam has led Quintiles’
expansion in size and service offerings across the region.
Quintiles now has more than 10,000 employees in 13 Asia-Pacific
countries with half the world’s population – including China and
Japan, respectively the world’s second- and third-largest biopharma
markets. In 2014, Quintiles Asia-Pacific’s service revenues were
$858 million USD.
“I am honored and humbled to have won this award,” Dr.
Tharmaratnam said at last night’s awards dinner in Singapore. “I’d
like to dedicate this award to my fellow Quintiles colleagues and
to our customers who entrust us with advancing their
investigational therapies to save lives and relieve suffering.
Together we are creating a healthier world.”
Quintiles has won BioPharma Asia’s “Best CRO in Asia” award
three times in the event’s five-year history, and last year – for
the sixth time in eight years – was named Asia-Pacific CRO of the
Year by Frost & Sullivan, a leading business research and
consulting firm.
At this week’s BioPharma Asia Convention, Quintiles’ experts Dr.
Karen Wai and Edwin Sia led roundtables on “Pan-Asian clinical
trials coordination” and “Improving clinical supply importation and
exportation,” respectively, and Wendy Bilham, Quintiles’ Head of
Therapeutic Science and Strategy, Asia-Pacific, presented a case
study on “Improving your probability of success in clinical trials
in Asia.”
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare outcomes. To
learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for
Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150324006239/en/
QuintilesJay Johnson, Media Relations, +65-6602-1297Mobile:
+65-9655-6635jay.johnson@quintiles.comorKarl Deonanan, Investor
Relations, +1-919-998-2789InvestorRelations@quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024